Probatebeta
Target

FLT1

Vascular endothelial growth factor receptor 1

As of the edition of 20 October 2026, FLT1 (vascular endothelial growth factor receptor 1, UniProt P17948) has 42 drugs tested at it and 43 companies on the list, 19 on route A and 6 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P17948
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
Inside the cell
Solved structures
12
Disease areas
Cancer; Digestive system; Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Hormones; Skin and connective tissue; Blood and lymph
Registered trials of its drugs
3,176

Drugs at this target

StatusCount
Marketed10
Active5
Went quiet10
Stopped15
Status not established2
Total42
DrugStatusFurthest phaseUS protection
SorafenibMarketedPhase 4Ends 2027
LenvatinibMarketedPhase 4Ends 2035
SunitinibMarketedPhase 4none listed
RegorafenibMarketedPhase 4Ends 2032
PazopanibMarketedPhase 4none listed
AxitinibMarketedPhase 3Ends 2030
NintedanibMarketedPhase 4Ends 2027
FruquintinibMarketedPhase 4Ends 2035
VandetanibMarketedPhase 3none listed
CediranibStoppedPhase 3none listed
SurufatinibActivePhase 4none listed
FamitinibStoppedPhase 3none listed

12 of 42 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A19
Route B6
Engaged11
Undetermined7
Total on the list43
Three companies on route A or B, with the route only
CompanyRoute
Jiangsu HengRui MedicineRoute A
TakedaRoute B
Bristol Myers SquibbRoute A

The other 40 companies at FLT1

In the product

43 companies in all; 40 are not named here, and no score is.

See the 43 companies at FLT1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at FLT1

Other targets in cancer

Companies holding approvals at FLT1